Eton Pharmaceuticals names Danka Radosavljevic as Chief Operating Officer
The appointment took effect July 31, 2026, elevating a longtime executive who has been with the company since 2017.
Eton Pharmaceuticals, Inc. disclosed in an 8-K filing that on July 31, 2026, the company appointed Danka Radosavljevic, age 42, as Chief Operating Officer.1
Radosavljevic moves into the role from a prior position at the company. She previously served as Executive Vice President, Operations, where she oversaw quality, product development, regulatory affairs, supply chain and information systems for more than the past five years.1 She has been with the company since 2017.1
The filing also detailed her new compensation package. Her pay includes an annual base salary of $520,800 and an annual discretionary incentive bonus with a total target amount of 50% of base salary, contingent on corporate and/or individual performance targets to be set and approved by the Board of Directors.1
The 8-K was signed on August 4, 2026 by Judith M. Matthews, the company's Chief Financial Officer and Secretary.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.